

September 18, 2018



# Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space

**- Conference call and webcast to be hosted by Management on Wednesday, September 26, 2018 at 4:15 PM ET**

**- Dr. Nirav Shah, Assistant Professor of Medicine, Division of Hematology and Oncology at Froedtert & the Medical College of Wisconsin to discuss clinical relevance and strategy related to latest pipeline initiative**

NEW YORK, Sept. 18, 2018 /PRNewswire/ --**Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company")**, announced today that it will unveil a new clinical initiative that expands the Company's pipeline into the CAR-T space. CAR-T is a type of cellular therapy that genetically alters a patient's own T cells to target and kill their cancer cells. Currently, there are 2 approved CAR-T therapies for patients with certain B-cell cancers and over 200 CAR-T candidates in preclinical and clinical development for a wide range of hematologic and solid tumor indications. Actinium's management team along with Dr. Nirav Shah, Assistant Professor of Medicine, Division of Hematology and Oncology at Froedtert & the Medical College of Wisconsin will discuss the Company's latest pipeline initiative, its value proposition as applicable to CAR-T and the expected development pathway.



Dr. Shah said, "CAR-T is an exciting medical advancement that has demonstrated incredible promise in patients that need better treatment options and outcomes. The Froedtert & the Medical College of Wisconsin was an early adopter of CAR-T becoming one of the first FACT certified medical centers in the nation and commercial CAR-T sites, consistent with its pioneering of other techniques such as stem cell transplantation and immunotherapy. My colleagues and I, at the Froedtert & the Medical College of Wisconsin, are committed to continuing to advance the exciting field of CAR-T to further improve patient outcomes. I am excited by the potential of Actinium's next generation technology to further advance the field of CAR-T and look forward to providing more details on this potentially disruptive clinical initiative."

In addition to Dr. Shah, Sandesh Seth, Actinium's Chairman and CEO and Dr. Dale Ludwig, Actinium's Chief Scientific Officer will be on the call to discuss this new pipeline initiative. Participation details for the conference call and webcast are as follows:

**Date:** Wednesday, September 26, 2018

**Time:** 4:15 PM ET

**Webcast Registration:**

<https://onecast.thinkpragmatic.com/ses/8JeRIX31t6pPIM3Dm85kJA~~>

**U.S. Participant Dial-in:** (718) 865-8336

**U.S./Canada Toll Free Dial-in:** (855) 427-0225

**Conference ID:** 4831

"We are excited to be forging a path into CAR-T and are thrilled to be working with Dr. Shah and his colleagues at the Froedtert & Medical College of Wisconsin who have been pioneers in this field. We look forward to the contributions they will make to our next generation technology that we believe has great potential to advance access to CAR-T and patient outcomes" said, Sandesh Seth, Actinium's Chairman and CEO. "I am incredibly motivated by this important pipeline expansion which has been enabled by the efforts of our new team and the potential growth opportunities it can provide for Actinium."

#### **About Actinium Pharmaceuticals, Inc.**

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior targeted conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. The Company's targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.

Iomab-B, Actinium's lead product candidate, is currently enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is designed to condition the bone marrow prior to a bone marrow transplant without the need for intense chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) of age 55 or older. Actinium's pipeline also includes a potentially best-in-class CD33 program with our ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in Phase 2 and Phase 1 clinical trials for patients with AML, myelodysplastic syndrome (MDS) and multiple myeloma.

Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly differentiated radioisotope actinium-225 with a wide range of targets. AWE is being utilized in a collaborative research partnership with Astellas Pharma, Inc.

More information is available at [www.actiniumpharma.com](http://www.actiniumpharma.com) and our Twitter feed @ActiniumPharma, [www.twitter.com/actiniumpharma](https://www.twitter.com/actiniumpharma).

**Forward-Looking Statements for Actinium Pharmaceuticals, Inc.**

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

**Contact:**

**Actinium Pharmaceuticals, Inc.**

Steve O'Loughlin

Vice President, Finance and Corporate Development

[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)

**Investor Relations**

Rx Communications Group

Paula Schwartz


917-322-2216

[pschwartz@rxir.com](mailto:pschwartz@rxir.com)

Susan A. Noonan

212-966-3650

[investorrelations@actiniumpharma.com](mailto:investorrelations@actiniumpharma.com)

 View original content to download multimedia <http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-host-webinar-showcasing-new-pipeline-initiative-focused-on-the-car-t-space-300714317.html>

SOURCE Actinium Pharmaceuticals, Inc.